CTR9 Activators would represent a class of chemical compounds specifically designed to enhance the activity of the CTR9 protein. CTR9 is a part of the PAF1 complex, a multifunctional protein complex involved in various aspects of RNA polymerase II transcription, including the elongation phase of transcription and histone modifications. The PAF1 complex has a crucial role in maintaining the fidelity of transcription and is implicated in the regulation of gene expression. Activators of CTR9 would bind to the protein and promote its role within the PAF1 complex, potentially by enhancing its interaction with other components of the complex or by stabilizing the complex itself. This would lead to a more efficient transcriptional regulation by RNA polymerase II, ensuring robust gene expression and proper cellular function. The specific chemical nature of CTR9 Activators could vary widely, ranging from small organic molecules to larger biomolecules, all designed to interact with CTR9 in a way that augments its natural function.
Developing such activators would require a comprehensive understanding of the structure and function of CTR9 within the PAF1 complex. Methods like X-ray crystallography, cryo-EM, and NMR spectroscopy might be utilized to gain insight into the atomic-level details of CTR9 and its interaction sites. With this information, a targeted approach could be taken to design compounds that bind effectively to CTR9. High-throughput screening methods could be employed to assay thousands of compounds for their ability to modulate the activity of CTR9. Once potential activators are identified, they would undergo a rigorous process of optimization to improve their efficacy, specificity, and stability. This optimization would likely involve iterative cycles of compound modification, followed by structural and functional assays to evaluate the effects of the modifications on CTR9 activation.
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
As an inhibitor of DNA methyltransferase, 5-azacytidine may alter chromatin states and indirectly influence CTR9 expression. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
This histone deacetylase inhibitor could affect chromatin structure and potentially increase the expression of many genes, including CTR9. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid modulates gene expression and differentiation, potentially influencing CTR9 expression as part of broader gene regulation. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $30.00 $46.00 $82.00 $218.00 | 19 | |
Sodium butyrate, a histone deacetylase inhibitor, may change chromatin structure and thereby impact CTR9 expression. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D intercalates into DNA, inhibiting transcriptional processes which could lead to altered CTR9 expression. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
An inhibitor of DNA topoisomerase I, camptothecin creates DNA damage and may influence CTR9 expression as part of the DNA damage response. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide inhibits eukaryotic protein synthesis, which can lead to a stress response potentially altering CTR9 expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
By inhibiting the mTOR pathway, rapamycin could indirectly influence the expression of genes involved in transcriptional regulation, including CTR9. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine, by increasing lysosomal pH, may affect cellular stress pathways and influence CTR9 expression. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
As an Hsp90 inhibitor, geldanamycin may disrupt protein folding and affect the stability of proteins involved in gene regulation, potentially impacting CTR9 levels. |